Trial · NCT02159950
Outcomes14
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Immune Response Assessed by IFN-g ELISPOT Specific for PA2024 | Baseline up to 50 weeks | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Change in PSA Response | Baseline to up to 3 years | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Duration of PSA Response | Up to 3 years | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Frequency of Toxicities Assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4 | Up to 3 years | All treated and eligible patients. | participants | NUMBER |
| SECONDARY | Immune Response | Week 6 | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Immune Response | Week 10 | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Immune Response | Week 26 | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Immune Response | Week 50 | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Immune Response (Arm 2 Only) | Week 0 | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Objective Response Rates (Partial or Complete) | Up to 3 years | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Overall Survival | Up to 3 years | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Progression-free Survival | Up to 3 years | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| SECONDARY | Time to PSA Progression | Up to 3 years | Due a Lack of funding data was not collected and no patients were analyzed. | ||
| OTHER_PRE_SPECIFIED | Effects of Tasquinimod on the Inhibition of Immune Cells | Up to week 50 | Due a Lack of funding data was not collected and no patients were analyzed. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02159950/outcomes